← All trials
NCT04245033
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 10, 2020
- Primary completion
- Jan 31, 2021
- Completion date
- Feb 28, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 4032
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Institute for Medical Research, TanzaniaLead sponsor
- National Institute for Medical Research, TanzaniaOverall official - principal investigator
- National Institute for Medical Research, TanzaniaReponsible party - principal investigator
- Government of TanzaniaCollaborator
- Government of TanzaniaStudy director
- National Institute for Medical Research, TanzaniaStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.